Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8097
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStein, Pamela-
dc.contributor.authorGogoll, Karsten-
dc.contributor.authorTenzer, Stefan-
dc.contributor.authorSchild, Hansjörg-
dc.contributor.authorStevanovic, Stefan-
dc.contributor.authorLangguth, Peter-
dc.contributor.authorRadsak, Markus-
dc.date.accessioned2022-10-19T07:46:29Z-
dc.date.available2022-10-19T07:46:29Z-
dc.date.issued2014
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/8112-
dc.description.abstractBackground: Transcutaneous immunization (TCI) approaches utilize skin associated lymphatic tissues to elicit specific immune responses. In this context, the imidazoquinoline derivative imiquimod formulated in Aldara applied onto intact skin together with a cytotoxic T lymphocyte (CTL) epitope induces potent CTL responses. However, the feasibility and efficacy of the commercial imiquimod formulation Aldara is limited by its physicochemical properties as well as its immunogenicity. Methodology/Principal Findings: To overcome these obstacles, we developed an imiquimod-containing emulsion gel (IMI- Gel) and characterized it in comparison to Aldara for rheological properties and in vitro mouse skin permeation in a Franz diffusion cell system. Imiquimod was readily released from Aldara, while IMI-Gel showed markedly decreased drug release. Nevertheless, comparing vaccination potency of Aldara or IMI-Gel-based TCI in C57BL/6 mice against the model cytotoxic T- lymphocyte epitope SIINFEKL, we found that IMI-Gel was equally effective in terms of the frequency of peptide-specific T- cells and in vivo cytolytic activity. Importantly, transcutaneous delivery of IMI-Gel for vaccination was clearly superior to the subcutaneous or oral route of administration. Finally, IMI-Gel based TCI was at least equally effective compared to Aldara- based TCI in rejection of established SIINFEKL-expressing E.G7 tumors in a therapeutic setup indicated by enhanced tumor rejection and survival. Conclusion/Significance: In summary, we developed a novel imiquimod formulation with feasible pharmaceutical properties and immunological efficacy that fosters the rational design of a next generation transcutaneous vaccination platform suitable for the treatment of cancer or persistent virus infections.en_GB
dc.description.sponsorshipDFG, Open Access-Publizieren Universität Mainz / Universitätsmedizinde
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleEfficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulationen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-8097-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.departmentFB 09 Chemie, Pharmazie u. Geowissensch.de
jgu.organisation.number2700-
jgu.organisation.number7950-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titlePLoS onede
jgu.journal.volume9de
jgu.journal.issue7de
jgu.pages.alternativee102664de
jgu.publisher.year2014-
jgu.publisher.namePLoSde
jgu.publisher.placeLawrence, Kan.de
jgu.publisher.urihttp://dx.doi.org/10.1371/journal.pone.0102664de
jgu.publisher.issn1932-6203de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
opus.date.modified2018-08-08T09:05:45Z
opus.subject.dfgcode04-205
opus.organisation.stringFB 04: Medizin: Institut für Immunologiede_DE
opus.organisation.stringFB 04: Medizin: III. Medizinische Klinik und Poliklinikde_DE
opus.organisation.stringFB 09: Chemie, Pharmazie und Geowissenschaften: Institut für Pharmaziede_DE
opus.identifier.opusid26437
opus.institute.number0412
opus.institute.number0427
opus.institute.number0908
opus.metadataonlyfalse
opus.type.contenttypeKeinede_DE
opus.type.contenttypeNoneen_EN
opus.affiliatedTenzer, Stefan
opus.affiliatedSchild, Hansjörg
opus.affiliatedLangguth, Peter
opus.affiliatedRadsak, Markus
jgu.publisher.doi10.1371/journal.pone.0102664de
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:DFG-OA-Publizieren (2012 - 2017)

Files in This Item:
  File Description SizeFormat
Thumbnail
efficacy_of_imiquimodbased_tr-20220925171531066.pdf1.07 MBAdobe PDFView/Open